ChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.065 CAD | 0.00% | 0.00% | 0.00% |
Feb. 28 | Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors | CI |
Feb. 28 | Chitogenx Inc. Announces CEO Changes | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 3.95M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CHGX Stock
- News ChitogenX Inc.
- ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study